Skip to main content

Correction to: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis

Correction to: Breast Cancer Res

https://doi.org/10.1186/s13058-020-1246-5

After the publication of the original article [1], we were notified the upper panel of the Fig. 1, where the patients’ codes are listed, was cropped by mistake so the patients 1–8 are repeated. The 88 patients should be listed, instead.

Below is the correct version of Fig. 1.

Fig. 1
figure1

ESR1 mutation analysis in the metastatic cohort and its clinical significance. a Analysis of matched samples from the metastatic cohort through the course of disease: primary tumor, newly diagnosed metastases, and advanced metastases. Samples are colored according to their mutation type. Red indicates ESR1 Mut. Green indicates ESR1 WT. ESR1 mutations at an allele frequency of > 1% are marked by an asterisk. Dark gray indicates that a tumor was present at this time point but a sample was not available. Lower bars represent the treatments given for each patient pre-biopsy, either at the adjuvant phase before the metastatic disease or at the advanced phase before the advanced metastatic biopsy. TAM, tamoxifen, light blue; AI, aromatase inhibitor, blue. b Prevalence of ESR1 mutations divided according to the metastatic disease stage and the type of treatment prior to biopsy. c Kaplan-Meier plots of progression-free survival calculated from the start of AI treatment at the metastatic setting

Reference

  1. 1.

    Zundelevich, et al. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis. Breast Cancer Res. 2020;22:16. https://doi.org/10.1186/s13058-020-1246-5.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Einav Nili Gal-Yam.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zundelevich, A., Dadiani, M., Kahana-Edwin, S. et al. Correction to: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis. Breast Cancer Res 22, 28 (2020). https://doi.org/10.1186/s13058-020-01265-y

Download citation